This objective is to study the influence of pH on the electrochemical behavior of 00Cr15Ni7Mo2Cu2 supermartensitic stainless steel in 3.5% NaCl solutions using potentiondynamic polarization technique, open circuit potential tests and electrochemical impedance spectroscopy (EIS).The study reveals that the pitting potential (Eb) is higher, the passivation current densities (ip) is lower and the electrochemical impedance increases with the pH. The results indicate that this stainless steel offer good pitting corrosion resistance with the pH increasing in 3.5% NaCl solutions.
The interplay of Cu and Ni on the formation of reversed austenite in super martensitic stainless steel (SMSS) was discussed in this study. Ni concentration in reversed austenite increases from 9.93 to 11.96 wt-% as Cu content increases from 1.5 to 3 wt-%, while Cu concentration increases from 1.43 to 1.89 wt-% as Ni increases from 5 to 6.5 wt-%. The enrichment of Ni and Cu in reversed austenite is much higher than that in martensite matrix. Reversed austenite formed in the dispersion area of ε-Cu inherits the twinning structure of ε-Cu and the crystal orientation relationship with the matrix during tempering. So Cu helps increase the enrichment of Ni, which in turn promotes Cu enrichment and induces the precipitation of ε-Cu due to the reduction of interfacial energy for reversed austenite formation. Our work reveals the synergism of Cu and Ni on the formation of reversed austenite.
We aimed to evaluate the effects of fulvestrant on the glycolysis of prolactinoma GH3 cells, and reveal the potential regulatory mechanisms.Prolactinoma cell line GH3 was treated with different concentrations of fulvestrant (0, 0.12, 0.25, 0.5 and 1 ng/ml) for 4 h. siRNAs XBP1s and XBP1u were constructed to treat GH3 cells. The expression levels of XBP1s, XBP1u, IRE1, PKM2 and GRP78 of GH3 cells were detected by Western blot. Meanwhile, the glycolytic activity of GH3 cells, including the glucose uptake, ATP/ADP, and lactate production were detected.The expression levels of XBP1s and XBP1u were significantly inhibited by fulvestrant in a dose-dependent manner. The glucose uptake, ATP/ADP and lactate production of GH3 cells were significantly inhibited by fulvestrant as well as siRNA XBP1s and XBP1u (p < 0.05). Western blot analysis suggested that the expression levels of IRE1, PKM2 and GRP78 were significantly decreased in GH3 cells treated by fulvestrant as well as siRNA XBP1s and XBP1u, compared with those in normal control (p < 0.05).Fulvestrant could inhibit the glycolysis of GH3 cells by downregulating IRE1/XBP1 signaling pathway, and this process was closely related with the downregulation of PKM2.
The morphology and size distribution of inclusions in G50 steel produced by different metallurgy processes were analyzed by SEM,EDAX.Results indicated that in the G50 produced by VIM+VAR the size of MnS inclusions was slightly smaller and their aspect ratio,mean spacing were distinctly larger.There were much more fine inclusions concentrated locally.Size distribution and morphology of MnS in G50 produced by VIM +VAR were dispersed evenly due to higher calcium content in composite MnS inclusions,leading to poor deformability.
One hundred and seven patients with prostate cancer were treated at Mie University Hospital during the past 12 years between 1988 and 1999. They were between 53 and 83 years old, with an average age of 70.8 years old. The clinical stage was defined as A, B, C and D in 3 (2.8%), 19 (17.8%), 50 (46.7%) and 35 (32.7%) patients, respectively. At initial diagnosis, the tumor was well, moderately and poorly differentiated adenocarcinoma in 26 (24.3%), 47 (43.9%) and 34 (31.8%) patients, respectively. The median follow-up period was 52.3 months. The overall 1, 3 and 5-year survival rates were 98.0%, 86.8% and 75.2%, respectively. The 5-year survival rates for stage A, B, C and D were 100%, 93.8%, 82.1% and 56.9%, respectively. A significant difference (p = 0.017) in 5-year survival rate was noted between stage C and D. The 5-year survival rate was 100% for well differentiated, 78.0% for moderately differentiated, and 53.2% for poorly differentiated adenocarcinoma. A significant difference (p = 0.0016) in the 5-year survival rate was noted between well differentiated and poorly differentiated adenocarcinoma. According to the therapy, the 5-year survival rate in stage C was 86.2% for the radical prostatectomy group and 84.0% for the endocrine therapy group. There was no significant difference between these 2 treatment groups. Endocrine therapies, classified into maximum androgen blockade (MAB) and endocrine therapy other than MAB were performed for stage D as an initial therapy. Although the prognosis in the patients treated with MAB was better than that with other endocrine therapies, there was no significant difference between these 2 endocrine treatment groups.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)